SSJ - Genomics Controller (R).pdf

JUSTIFICATION FOR SOLE SOURCE PROCUREMENT (OPEN MARKET OR GSA)

UNDER $250,000

Sole source acquisitions may be used on a limited basis and only when the Contracting Officer’s Representative (COR)/Program Official has provided sufficient justification and the Contracting Officer has determined that the circumstances warrant such action. The content for a justification must contain detailed facts and rationale to justify the sole source acquisition. Soliciting from a single source must be done in accordance with FAR 13.106-1(b) or 8.405-6. At a minimum, the following information must be included:

Identification of Program Office, Contracting Activity, and Proposed Requirement, Justification and Program Office Certification:

A. Program Office:

1600 Clifton Road, Roybal Building 17, RM 5228 Immunology and Pathogenesis Branch Influenza Division, NCIRD Centers for Disease Control and Prevention Atlanta, GA 30329

B. Contracting Activity:

Centers for Disease Control and Prevention

Office of Financial Resources

Acquisition Branch: Centers for Disease Control and Prevention Procurement and Grants Office

Acquisition and Assistance Branch II 2920 Brandywine Road Atlanta, GA 30341

C. Identification of Requirement:

1. Nature of Action to be Approved by Contracting Officer:

a. Sole source acquisition of: Purchase of 10X Chromium Connect System

b. Procurement Request (PR) Number (if available): Click here to enter text.

2. Proposed Vendor and Estimated Procurement Amount (if available):

a. Proposed Vendor: 10x Genomics, Inc. 6230 Stoneridge Mall Road Pleasanton, California, 94588-3260 United States

b. Estimated Procurement Amount: $249950.00

3. Is the requirement on GSA Schedule? ☐ Yes ☒ No

If yes, provide schedule number: Click here to enter text.

Rev. 5/14/19

D. Justification:

1. The justification for this non-competitive action is:

☒ In accordance with FAR 13.106-1(b)(1), “only one source [is] reasonably available” which states that, “For purchases not exceeding the simplified acquisition threshold. (i) Contracting officers may solicit from one source if the contracting officer determines that the circumstances of the contract action deem only one source reasonably available (e.g., urgency, exclusive licensing agreements, brand-name or industrial mobilization). (ii) Where a single source is identified to provide a portion of a purchase because that portion of the purchase specifies a particular brand-name item, the documentation in paragraph (b)(1)(i) of this section only applies to the portion of the purchase requiring brand-name item. The documentation should state it is covering only the portion of the acquisition which is brand- name.”

☐ Urgency

☐ Exclusive licensing agreements/Proprietary data

☒ Brand name required

☐ Industrial mobilization

☒ Other (e.g., compatibility, space issues, continuity, compatibility, etc.)

☐ In accordance with FAR 8.405-6 “Limiting Sources” which states that, “the only circumstances that may justify the action are – (A) An urgent and compelling need exists, and following the procedures would result in unacceptable delays; (B) Only one source is capable of providing the supplies or services required at the level of quality required because the supplies or services are unique or highly specialized; or (C) In the interest of economy and efficiency, the new work is a logical follow-up to an original Federal Supply Schedule order provided that the original order was placed in accordance with the applicable Federal Supply Schedule ordering procedures. The original BPA must not have been previously issued under sole-source or limited-sources procedures.”

☐ Urgency

☐ Only One Source

☐ Logical Follow Up

☐ Brand name required

2. Other facts supporting sole source procurement:

a. What can this product/service do that other products/services cannot do?

There is no competitive platform on the market that does what the Connect is enable to including automated high throughput single cell workflow from single cell/nuclei suspension to sequencing-ready libraries in one day for gene expression analysis and/or immune repertoire profiling. There are liquid handlers that can automate the library construction steps but the single cell capture and cDNA synthesis will need to be done manually.

For the Chromium Controller and the manual single cell workflow, competitors include BD Rhapsody and Bio-Rad ddSeq, as well as the inDrop. These platforms do not offer the throughput (up to 80,000 cells/run for any single cell applications and up to 240,000 cells/run with 3’ CellPlex) that the Chromium Controller enables that is critical to characterize immune repertoire diversity and the heterogeneity of complex tissues/samples.

The Chromium Controller is designed for multi-omics applications that enables the analysis of multiple modalities from the same cell, including whole transcriptome or targeted panel analysis, epigenomics, cell surface protein marker analysis using

Feature Barcoding technology, antigen specificity, multiome profiling (simultaneous gene expression and chromatin accessibility assessment), or the upcoming antigen mapping solution for high-throughput antibody and TCR discovery.

For immune profiling, the 10x single cell solution is the only solution that enables to simultaneously analyze WTA and full-length paired VDJ transcripts from the same cell from 500-80,000 cells/run (most system can capture less than 20,000 cells/run). In addition, the BD Rhapsody only captures cells less than 20 µm and therefore limiting the cell subpopulations captured and introducing cell size bias towards smaller cells while the 10x platform offers a cell size limitation of up to 50 µm. Additionally, with a capture rate of 65%, the Chromium Controller offers the best cell recovery on the market.

Finally, over 2,500 publications have now used the 10x Chromium Controller for single cell analysis, significantly more than any other technology on the market.

b. What other products/services were considered and why did they not meet the need?

BD Rhapsody and Bio-Rad ddSeq, as well as the inDrop from 1 cell Bio were considered and they did not meet our needs as these platforms do not offer the throughput (up to 80,000 cells/run for any single cell applications and up to 240,000 cells/run with 3’ CellPlex) that the Chromium Controller enables that is critical to characterize immune repertoire diversity and the heterogeneity of complex tissues/samples.

For immune profiling, the 10x single cell solution is the only solution that enables to simultaneously analyze WTA and full-length paired VDJ transcripts from the same cell from 500-80,000 cells/run (most system can capture less than 20,000 cells/run). In addition, the BD Rhapsody only captures cells less than 20 µm and therefore limiting the cell subpopulations captured and introducing cell size bias towards smaller cells while the 10x platform offers a cell size limitation of up to 50 µm. Additionally, with a capture rate of 65%, the Chromium Controller offers the best cell recovery on the market.

3. Program Office efforts to seek potential offerors:

BD Rhapsody and Bio-Rad ddSeq, as well as the inDrop from 1 cell Bio were considered and they did not meet our needs as these platforms do not offer the throughput (up to

80,000 cells/run for any single cell applications and up to 240,000 cells/run with 3’ CellPlex) that the Chromium Controller enables that is critical to characterize immune repertoire diversity and the heterogeneity of complex tissues/samples. For immune profiling, the 10x single cell solution is the only solution that enables to simultaneously analyze WTA and full-length paired VDJ transcripts from the same cell from 500-80,000 cells/run (most system can capture less than 20,000 cells/run). In addition, the BD Rhapsody only captures cells less than 20 µm and therefore limiting the cell subpopulations captured and introducing cell size bias towards smaller cells while the 10x platform offers a cell size limitation of up to 50 µm. Additionally, with a capture rate of 65%, the Chromium Controller offers the best cell recovery on the market.

E. Program Office Certification:

I have reviewed this sole source justification and certify the justification is true and accurate to the best of my knowledge and adequate to support other than full and open competition.

Center/Institute/Office COR/Program Official Name/Title: Priya Ranjan, Research Biologist, IPB, ID, NCIRD

Center/Institute/Office COR/Program Official Signature:

Certification Date: March 10, 2021

F. Contracting Office Certification:

I have fully relied on the information provided herein and hereby certify that this justification is accurate and complete to the best of my knowledge and belief:

Contracting Officer Name: Click here to enter text.

Contracting Officer Signature:

Certification Date: Click here to enter a date.

4/12/2021